Melphalan Tillomed (Melphalan)

Melphalan belongs to the alkylating agent class. It binds to DNA and creates cross‑links between strands, which blocks DNA replication and transcription. This damage triggers cell‑cycle arrest and apoptosis, especially in rapidly dividing cancer cells.

The dose of Melphalan Tillomed is individualized by the prescribing oncologist based on the specific indication, patient weight, renal function and treatment protocol. Only a qualified healthcare professional should determine the appropriate dosing schedule.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception throughout treatment and for a period afterward as advised by their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Melphalan shares the DNA‑alkylating mechanism common to its class, but its pharmacokinetic profile and approved indications differ. Compared with cyclophosphamide, melphalan has a higher potency for certain solid tumours and is often chosen for high‑dose regimens in multiple myeloma, whereas cyclophosphamide is more frequently used in lymphomas and breast cancer.

Melphalan Tillomed should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and sterility.

Melphalan Tillomed is administered intravenously by a qualified healthcare professional. The infusion rate and duration are determined by the treatment protocol and patient tolerance, and the drug is typically given in a controlled clinical setting to monitor for immediate reactions.

The most serious risks include severe bone‑marrow suppression leading to life‑threatening infections, secondary malignancies, and pulmonary toxicity such as interstitial pneumonitis. Patients should be closely monitored for signs of infection, respiratory symptoms and any unexpected laboratory abnormalities.

Melphalan Tillomed is contraindicated in patients with known hypersensitivity to melphalan or any component of the formulation, in those receiving live vaccines, and in pregnant women. Caution is also advised for individuals with severe renal or hepatic impairment, as dose adjustments may be required.